Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2000, p. 2023-2027, Vol. 44, No. 8
Laboratory of Drug Resistance in Bacteria,
Gunma University School of Medicine, Maebashi,1
Division of Microbial Chemistry, Faculty of Pharmaceutical
Sciences, Chiba University, Chiba,2 and
Research Laboratory, Toyama Chemical Co., Ltd.,
Toyama,3 Japan
Received 8 October 1999/Returned for modification 31 January
2000/Accepted 5 May 2000
In the course of surveying for the carbapenem-hydrolyzing
metallo- Molecular class B metallo- Genes blaESP and blaIMP,
respectively encoding ESP and IMP-1 Bacterial strains and plasmids.
Plasmids pMS390 from
S. flexneri JS19622 and pMS350 from P. aeruginosa
GN17203 are the starting plasmids used for this study. Plasmid pMS390
was transferred by conjugation to an Escherichia coli K-12
ML4905 strain for enzyme analysis (21), and the gene was
cloned in E. coli K-12 JM83 for sequencing (this work). The metallo-
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Amino Acid Substitutions in a Variant of
IMP-1 Metallo-
-Lactamase
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactamase gene blaIMP in pathogenic
bacteria by the PCR method, we detected a gene encoding a variant
metallo-
-lactamase, designated IMP-3, which differed from IMP-1 by
having low hydrolyzing activity for penicillins and carbapenems. PCR
product direct sequencing of a 2.2-kb segment revealed that the gene
blaIMP-3 was located on a cassette inserted
within a class I integron in the pMS390 plasmid. The 741-bp nucleotide
sequence of blaIMP-3 was identical to that of
blaIMP-1, except for seven base substitutions.
Among these were two, at nucleotide positions 314 and 640, which caused amino acid alterations. Hybrid bla genes were constructed
from blaIMP-3 and
blaIMP-1 by recombinant DNA techniques, and
-lactamases encoded by these genes were compared with those of the
parents IMP-3 and IMP-1 under the same experimental conditions. The
kinetic parameters indicated that the inefficient hydrolysis of
benzylpenicillin, ampicillin, imipenem, and ceftazidime by IMP-3 was
due to the substitution of glycine for serine at amino acid residue 196 in the mature enzyme. This alteration corresponded to the presence of
guanine instead of an adenine at nucleotide position 640 of the
blaIMP-3 gene. This indicated that extension of
the substrate profile in the metallo-
-lactamase IMP-1 compared to
IMP-3 is the result of a one-step single-base mutation, suggesting that the gene blaIMP-3 is an ancestor of
blaIMP-1.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-Lactamases are enzymes that
hydrolyze
-lactam antibiotics, conferring resistance to a variety of
these antibiotics for most pathogenic bacteria. These enzymes have been
classified phylogenetically based on their functional and molecular
characteristics (5).
-lactamases belonging to functional group
3a subclass B1 are characteristic in their broad substrate spectrum,
which extends to most
-lactam antibiotics, except for monobactams,
and have activities as penicillinases, cephalosporinases, and
carbapenemases (5, 15, 23). They have been reported in
Bacillus cereus, alkalophilic Bacillus sp.,
Bacteroides fragilis, Pseudomonas aeruginosa,
Serratia marcescens, and Klebsiella pneumoniae (23). Among this group of metallo-
-lactamases, ESP from
P. aeruginosa GN17203, IMP-1 from S. marcescens
TN9106, and DK4 from K. pneumoniae are all plasmid mediated
and were found to be the same enzyme because the nucleotide sequences
of their genes are identical (14, 22; GenBank accession number
D29636).
-lactamase, were identified in
the cassettes inserted in the integrons on plasmids (24).
Both cassettes had the same nucleotide sequence, but they were found to
be inserted into different integrons, class 1 integron 0 (In0) for the
blaESP cassette (2, 14) and the class
3 integron for the blaIMP cassette
(1). This fact suggested that the
blaIMP (blaESP) cassette
has been disseminated among different integrons. Since In0 is reported
to be widespread among clinical isolates of gram-negative bacilli and
has insertions of single or multiple drug resistance genes
(17), we surveyed clinical isolates for In0 bearing
blaIMP (blaESP) by the
PCR method, followed by an assay of
-lactamase activity. In the
process of these assays, we demonstrated the presence of a novel
metallo-
-lactamase which was mediated by Shigella
flexneri plasmid pMS390 (21). The
-lactamase,
originally named MET-1 is a cephalosporinase, showing preferential
hydrolysis of cephalosporins rather than penicillins or carbapenems. We
examined the nucleotide sequence of the gene
blaMET to identify the amino acid substitutions
affecting the substrate specificity in the MET-1
-lactamase. On the
basis of our findings, the gene and the enzyme were renamed
blaIMP-3 and IMP-3
-lactamase, respectively,
to mesh with prior discoveries and nomenclature.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactamase gene blaESP of pMS350
(29) had been earlier cloned and sequenced (13,
14). Since the nucleotide sequence of
blaESP was identical to that of
blaIMP from S. marsescens strain TN9106 (22), hereafter in this work the abbreviation
blaIMP is used for blaESP
from pMS350.
Hd.
Recombinant plasmids pMS400, pMS500, pMS401, pMS501, pMS402, and pMS502
were constructed for these experiments.
Antibacterial agents.
The
-lactam antibiotics used and
their sources were as follows: cephaloridine and cephalothin, Shionogi
& Co., Ltd.; cefotaxime, Hoechst Marion Roussel Ltd.; ceftazidime,
Nippon Glaxo Ltd.; benzylpenicillin, Meiji Seika Kaisha, Ltd.;
ampicillin, Toyama Chemical Co., Ltd.; imipenem, Banyu Pharmaceutical
Co., Ltd.; and aztreonam, Bristol-Myers Squibb K. K.
Susceptibility tests. MICs were determined by an agar dilution method with sensitivity disk agar (Nissui Pharmaceutical Co.) (29).
Purification of
-lactamase and assay of activity.
Preparation and purification of
-lactamases using E. coli
JM83 strains harboring recombinant plasmids were performed according to
a previously reported method (21).
-Lactamase activity was determined spectrophotometrically at 30°C
in 50 mM morpholinepropanesulfonic acid (MOPS) buffer (pH 7.0). The
kinetic parameters were determined according to a procedure reported
previously (21). Statistical data were obtained by the
online analysis (UV absorption method and Lineweaver-Burk plot analysis
on the computer) system by measuring the rate of hydrolysis
(kcat) and Km values more
than three times. When Km values were too large
for this system, they were obtained from Michaelis-Menten graphs by
measuring the initial hydrolysis rates.
PCR amplification of the DNA segment. Primer sequences for PCR amplification were CGGATGAAGGCACGAAC (forward) and AAGCAGACTTGACCTGA (reverse), constructed for detection of the blaIMP cassette inserted in the integron In0 (14). The forward primer was part of the 5' conserved sequence of the In0 located 5 nucleotides upstream from the promoter region for blaIMP (18), and the reverse primer was part of the 3' conserved sequence of the integron downstream from the blaIMP gene cassettes (2, 17).
The PCR procedure consisted of 25 cycles of denaturation at 94°C for 1.5 min, annealing at 55°C for 1.5 min, and amplification at 72°C for 1.5 min, followed by an additional 7 min at 72°C using Premix Taq reagent (Takara Shuzo Co., Ltd.) with the Program Template Control System PC-700 (ASTEC Co., Ltd.).Nucleotide sequencing. The PCR-amplified DNA segment was sequenced by a direct sequencing method using the Autosequencer ABI377 in the Gene Analysis Center of Takara Shuzou Co., Ltd.
Cloning of the PCR-amplified segment.
The PCR product
obtained by agarose gel electrophoresis was purified by adsorbing the
DNA to a silica matrix using a DNA purification kit (Gene Mate; ISC
BioExpress) and was ligated with pT7Blue T-Vector (Novagen) according
to the manufacturer's protocol. Recombinant plasmids were introduced
into the host strain E. coli NovaBlue, and the transformants
were obtained as white colonies on a Luria agar plate containing X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) (50 µg/ml), IPTG (isopropyl-
-D-thiogalactopyranoside) (50 µg/ml), tetracycline (15 µg/ml), and ampicillin (50 µg/ml).
| |
RESULTS |
|---|
|
|
|---|
Identification and nucleotide sequencing of the
-lactamase
gene of pMS390.
A DNA segment, approximately 2.2 kb in
size, was obtained from the pMS390-containing E. coli ML4905 cells after PCR amplification, using primers for
detection of the In0 sequence including the gene cassettes. The
nucleotide sequence was determined by the PCR product direct-sequencing
method. Within this segment, the gene composed of 741 bp was
detected. The sequence of the gene (DDBJ accession number AB010417) was
identical to that of blaIMP (1,
14) (DDBJ accession number D78375) except for seven nucleotide substitutions. The gene was designated
blaIMP-3 to correspond with the renaming
of the metallo-
-lactamase mediated by pMS390 (21),
which was originally named MET-1 and is now known as IMP-3
-lactamase.
-lactamases. Substitution of an A with a G at both
nucleotide positions 314 and 640 resulted in the replacement of the
amino acid: Glu with Gly and Ser with Gly at amino acid positions 87 and 196, respectively, in the mature metallo-
-lactamase (23).
Cloning of the PCR-amplified segment.
Three preparations of
2.2-kb segments, each obtained by independent PCR amplification, were
ligated with the pT7Blue vector, and the recombinant plasmids were
introduced by transformation into the host strain E. coli
NovaBlue. The transformants were examined for cefotaxime resistance,
which is conferred by the IMP-3
-lactamase. The MIC of cefotaxime
was raised from less than 0.5 µg/ml for the host strain to 64 µg/ml
for transformants.
Preparation of hybrid metallo-
-lactamase genes from
blaIMP-3 and
blaIMP-1.
The kcat
(per second) of penicillin relative to that of cephaloridine by highly
purified
-lactamases was reported to be rather low for IMP-3
(21) but high for IMP-1 (16, 23). As this difference is expected to be due to either or both of the two amino acid alterations between the two enzymes, we prepared hybrid genes from blaIMP-3 and
blaIMP-1 and compared them with those of the
parents IMP-3 and IMP-1 under the same experimental conditions.
|
Hd (step 2). Third, the H-S segment of the
recombinant plasmid obtained in step 2 was cut out and replaced with
the H-S segment of blaIMP-3 obtained in step 1 (step 3). Fourth, the S-E segment of pMS400 carrying the right part of
blaIMP-3 (from step 1) was inserted into the
step-3 plasmid, forming pMS401 which contained the whole
blaIMP-3 gene. The same S-E segment was inserted into the plasmid obtained at step 2, forming a hybrid plasmid pMS402
consisting of the left part of blaIMP-1 and the
right part of blaIMP-3.
The right S-E segment of pMS500 was obtained using the EcoRI
site in the multicloning region of the vector and inserted into the
step-3 plasmid. A hybrid plasmid pMS502 was thus obtained, and
consisted of the left part of blaIMP-3 and the
right part of blaIMP-1. The same S-E segment was
inserted into the step-2 plasmid, thereby forming plasmid pMS501 which
contained the whole blaIMP-1 gene.
The resulting four bla genes, from the two hybrids and their
parents, were capable of expression under the common promoter derived
from pMS500 provided by the integron portion (18).
Susceptibility to
-lactam antibiotics conferred by
-lactamases with amino acid substitutions.
With the
common background of the vector pHSG398
Hd and the host strain
E. coli K-12 JM83, MICs of various
-lactam
antibiotics were examined and compared among the four strains producing
different
-lactamases encoded by hybrid or parent bla
genes (Table 1). The MIC of imipenem was
rather low in the E. coli host carrying pMS500, as was
expected from previous findings using E. coli clones carrying the blaIMP-1 gene of P. aeruginosa plasmid pMS350 (13). A distinct rise in the
MIC of ampicillin was observed for strains carrying pMS501 and pMS502,
in which the
-lactamases had the amino acid Ser at position 196, in
comparison to MICs observed for strains carrying pMS401 and pMS402, in
which the
-lactamases had the amino acid Gly instead of Ser at that
position. The MICs of cephalothin for strains carrying pMS401 or pMS402
were fourfold higher than those for strains carrying pMS501 or pMS502.
Neither amino acid substitution caused distinct changes in the MICs of other
-lactams. Amino acid replacement at position 87 of the
-lactamases did not affect the MIC levels, as seen in the two strains bearing pMS401 or pMS402 and in those bearing pMS501 or pMS502.
The results suggested that the low MIC of ampicillin and high MIC of
cephalothin for strains carrying pMS401 and pMS402 resulted from a
single amino acid alteration from Ser to Gly at position 196.
|
Kinetic parameters of
-lactamases with amino acid
substitutions.
-Lactamase activities by enzymes encoded by the
four kinds of bla genes were assayed spectrophotometrically
using highly purified enzymes. Kinetic parameters for the hydrolysis of
various
-lactam antibiotics were determined under the same assay
conditions (Table 2). It was confirmed
that the kinetic parameters of IMP-3 and IMP-1 were in good agreement
with those previously estimated in an E. coli strain
carrying pMS390 (for both kcat and
Km) and in a P. aeruginosa strain
carrying pMS350 (for Km), respectively (21,
29). Aztreonam-hydrolyzing activities were undetectable in all
four enzymes (kcat < 0.06 s
1).
|
| |
DISCUSSION |
|---|
|
|
|---|
The IMP-3 (renamed from MET-1)
-lactamase of plasmid pMS390 had
been previously purified and revealed to be a cephalosporinase-type metallo-
-lactamase with low hydrolyzing activity for penicillins and
carbapenems (21). In contrast, the IMP-1
-lactamase,
which is widespread among clinical strains, differed in its broad
substrate spectrum of
-lactam antibiotics, including effective
hydrolysis of penicillins and carbapenems (16, 22, 29).
Sequence analysis of the gene blaIMP-3 revealed
that the enzymes were identical except for two amino acid substitutions
caused by two base replacements in the genes.
Hybrid bla genes obtained from
blaIMP-1 and blaIMP-3
were constructed under a common promoter by recombination DNA
techniques using a common vector and host strain of E. coli. Kinetic parameters for hydrolysis of various
-lactam
antibiotics by the purified enzymes were estimated under the same assay
conditions. The kinetic parameters of hybrid and parent
-lactamases
indicated that the more potent hydrolysis of ceftazidime,
benzylpenicillin, ampicillin, and imipenem could be acquired
by a single amino acid substitution, i.e., Ser for Gly at position 196. The other substitution, Glu for Gly at position 87, had no effect on
the substrate profiles examined so far, although further detailed
analysis of enzyme kinetics, including affinity to metallo ions,
remains to be carried out.
The amino acid sequences at the comparable regions of group 3a subclass
B1 metallo-
-lactamases have been identified (23). The
amino acid corresponding to that at position 196 in
-lactamases from
B. cereus, Bacillus sp., and B. fragilis is reported to be Gly, the same amino acid found in the
newly identified IMP-3
-lactamase, which differs from IMP-1
-lactamase. This amino acid lies just ahead of His, which has been
identified as interacting with a Zn2+ cofactor
(23). The association of the changed amino acid with the His
amino acid remains unexplored, and the coincidence may be interesting
to examine in terms of its affect on metallo ion interaction.
The results indicated that only a single-step mutation of the base G to
A at nucleotide position 640 of blaIMP-3
extended the substrate profile of the IMP-3 to that of the IMP-1-type
-lactamase and conferred resistance to ampicillin in E. coli. Evolution of
-lactamases from a narrow to an extended
spectrum of substrates was well analyzed in TEM- and SHV-type enzymes
belonging to the class A
-lactamases (3, 4, 8, 9, 15).
These
-lactamases, called extended-spectrum
-lactamases (ESBLs),
have been conferred with hydrolyzing activities against the
extended-spectrum
-lactam antibiotics by point mutations. Extension
of the substrate spectrum by amino acid substitutions also has been
reported in an OXA-type
-lactamase belonging to the class D enzymes
(6, 7, 10). In a class C
-lactamase of Enterobacter
cloacae, the substrate spectrum expansion was caused by a
duplication of three amino acids which was attributed to a tandem
duplication of a 9-nucleotide sequence in the parent enzyme
(20). None of the ESBLs derived from class A, C, and D
enzymes have hydrolyzing activities for carbapenems (5).
The metallo-
-lactamase IMP-1, which belongs to the class B
-lactamases, was characteristic in its carbapenem-hydrolyzing activity and had already been noted as an ESBL when it was first identified in a P. aeruginoisa plasmid (29) and
later in gram-negative rods (11, 12, 19, 25, 26).
Therefore, IMP-3 (originally designated MET-1)
-lactamase mediated
by plasmid pMS390 could be considered an ancestor of IMP-1
-lactamase. The gene could be mobilized as part of a cassette among
integrons located on various plasmids, becoming widely disseminated
among gram-negative bacteria, and conferring resistance to almost all
-lactam antibiotics.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant-in-aid for Scientific Research (08670300) from the Ministry of Education, Science, Sports, and Culture, Japan, and by a grant for Molecular Characterization of Antibiotic Resistance from the Ministry of Health and Welfare, Japan.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratory of Drug Resistance in Bacteria, Gunma University School of Medicine, 3-39-22, Showa-Machi, Maebashi, 371-8511, Japan. Phone: 81-27-220-8087. Fax: 81-27-220-8088. E-mail: siyobe{at}akagi.sb.gunma-u.ac.jp.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Arakawa, Y.,
M. Murakami,
K. Suzuki,
R. Wacharotayankun,
S. Ohsuka,
H. Ito,
N. Kato, and M. Ohta.
1995.
A novel integron-like element carrying the metallo- -lactamase gene blaIMP.
Antimicrob. Agents Chemother.
39:1612-1615[Abstract].
|
| 2. |
Bissonnette, L., and P. H. Roy.
1992.
Characterization of In0 of Pseudomonas aeruginosa plasmid pVS1, an ancestor of integrons of multiresistance plasmids and transposons of gram-negative bacteria.
J. Bacteriol.
174:1248-1257 |
| 3. |
Blanzquez, J.,
M. I. Morosini,
M. C. Negri,
M. Gonzalez-Leiza, and F. Baquero.
1995.
Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM -lactamases.
Antimicrob. Agents Chemother.
39:145-149[Abstract].
|
| 4. |
Bush, K., and G. A. Jacoby.
1977.
Nomenclature of TEM -lactamases.
J. Antimicrob. Chemother.
39:1-3.
|
| 5. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 6. |
Danel, F.,
L. M. C. Hall,
D. Gur, and D. M. Livermore.
1996.
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
39:1881-1884[Abstract].
|
| 7. |
Danel, F.,
L. M. C. Hall,
D. Gur, and D. M. Livermore.
1997.
OXA-15, an extended-spectrum variant of OXA-2 -lactamase, isolated from a Pseudomonas aeruginosa strain.
Antimicrob. Agents Chemother.
41:785-790[Abstract].
|
| 8. | Davies, J. 1995. Inactivation of antibiotics and the dissemination of resistance genes. Science 246:375-382[CrossRef]. |
| 9. |
Du Bois, S. K.,
M. S. Marriott, and S. B. Amyes.
1995.
TEM- and SHV-derived extended-spectrum -lactamases: relationship between selection, structure and function.
J. Antimicrob. Chemother.
35:7-22 |
| 10. |
Hall, L. M. C.,
D. M. Livermore,
D. Gur,
M. Akova, and H. E. Akalin.
1993.
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
37:1637-1644 |
| 11. |
Hirakawa, Y.,
K. Izumikawa,
T. Yamaguchi,
H. Takemura,
H. Tanaka,
R. Yoshida,
J. Matsuda,
M. Nakano,
K. Tomono,
S. Maesaki,
M. Kaku,
Y. Yamada,
S. Kamihira, and S. Kohno.
1998.
Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo- -lactamase gene blaIMP.
Antimicrob. Agents Chemother.
42:2006-2011 |
| 12. |
Ito, H.,
Y. Arakawa,
S. Ohsuka,
R. Wacharotayankun,
N. Kato, and M. Ohta.
1995.
Plasmid-mediated dissemination of the metallo- -lactamase gene blaIMP among clinically isolated strains of Serratia marcescens.
Antimicrob. Agents Chemother.
39:824-829[Abstract].
|
| 13. |
Iyobe, S.,
M. Tsunoda, and S. Mitsuhashi.
1994.
Cloning and expression in Enterobacteriaceae of the extended-spectrum -lactamase gene from a Pseudomonas aeruginosa plasmid.
FEMS Microbiol. Lett.
121:175-180[Medline].
|
| 14. |
Iyobe, S.,
S. Minami, and H. Yamada.
1996.
Insertion of a carbapenemase gene cassette into an integron of a Pseudomonas aeruginosa plasmid.
J. Antimicrob. Chemother.
38:1114-1115 |
| 15. |
Jacoby, G. A., and A. A. Medeiros.
1991.
More extended-spectrum -lactamases.
Antimicrob. Agents Chemother.
35:1697-1704 |
| 16. |
Laraki, N.,
N. Franceschini,
G. M. Rossolini,
P. Santucci,
C. Meunier,
E. De Pauw,
G. Amicosante,
J. M. Frere, and M. Galleni.
1999.
Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo- -lactamase IMP-1 produced by Escherichia coli.
Antimicrob. Agents Chemother.
43:902-906 |
| 17. | Levesque, C., L. Piche, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191[Abstract]. |
| 18. | Levesque, C., S. Brassard, J. Lapointe, and P. H. Roy. 1994. Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons. Gene 142:49-54[CrossRef][Medline]. |
| 19. |
Minami, S.,
M. Akama,
H. Araki,
Y. Watanabe,
H. Narita,
S. Iyobe, and S. Mitsuhashi.
1996.
Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids for class B -lactamases.
J. Antimicrob. Chemother.
37:433-444 |
| 20. |
Nukaga, M.,
S. Haruta,
K. Tanimoto,
K. Kogure,
K. Taniguchi,
M. Tamaki, and T. Sawai.
1995.
Molecular evolution of a class C -lactamase extending its substrate specificity.
J. Biol. Chem.
270:5729-5735 |
| 21. |
O'Hara, K.,
S. Haruta,
T. Sawai,
M. Tsunoda, and S. Iyobe.
1998.
Novel metallo -lactamase mediated by a Shigella flexneri plasmid.
FEMS Microbiol. Lett.
162:201-206[Medline].
|
| 22. |
Osano, E.,
Y. Arakawa,
R. Wacharotayankun,
M. Ohta,
T. Horii,
H. Ito,
F. Yoshimura, and N. Kato.
1994.
Molecular characterization of an enterobacterial metallo -lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.
Antimicrob. Agents Chemother.
38:71-78 |
| 23. |
Rasmussen, B. A., and K. Bush.
1997.
Carbapenem-hydrolyzing -lactamases.
Antimicrob. Agents Chemother.
41:223-232[Medline].
|
| 24. | Recchia, G. D., and R. M. Hall. 1995. Gene casettes: a new class of mobile element. Microbiology 141:3015-3027[Medline]. |
| 25. |
Senda, K.,
Y. Arakawa,
K. Nakashima,
H. Ito,
S. Ichiyama,
K. Shimokata,
N. Kato, and M. Ohta.
1996.
Multifocal outbreaks of metallo- -lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum -lactams, including carbapenems.
Antimicrob. Agents Chemother.
40:349-353[Abstract].
|
| 26. |
Senda, K.,
Y. Arakawa,
S. Ichiyama,
K. Nakashima,
H. Ito,
S. Ohsuka,
K. Shimokata,
N. Kato, and M. Ohta.
1996.
PCR detection of metallo- -lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum -lactams.
J. Clin. Microbiol.
34:2909-2913[Abstract].
|
| 27. |
Takeshita, S.,
M. Sato,
M. Oba,
W. Masahashi, and T. Hashimoto-Gotoh.
1987.
High-copy number and low-copy number plasmid vectors for lacZ -complementation and chloramphenicol- or kanamycin-resistance selection.
Gene
61:63-74[CrossRef][Medline].
|
| 28. | Vieira, J., and J. Messing. 1982. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis, and sequencing with synthetic universal primers. Gene 19:259-268[CrossRef][Medline]. |
| 29. |
Watanabe, M.,
S. Iyobe,
M. Inoue, and S. Mitsuhashi.
1991.
Transferable imipenem resistance in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
35:147-151 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |